
AI Impact Awards 2025: How 7 Health Care Winners Measure Impact
Artificial intelligence is an all-consuming force in the health care industry—and it's still gaining momentum. In 2024, the global health care AI market was estimated at more than $26 billion, and it's expected to grow to over $187 billion by 2030.
There's good reason for the boom. Health care executives, physicians and tech leaders alike agree that AI has enormous potential in the industry. It can help make outdated processes more efficient, generate new meaning from massive pools of data and even improve communications between industry stakeholders.
But as the AI market grows, it's becoming more challenging for health systems to parse through the noise and find solutions that will actually improve care outcomes.
Newsweek spoke with health care and life sciences winners of our inaugural AI Impact Awards to determine how they define and measure impact. Health care and life sciences were just one of the industries represented, and across more than a dozen categories, there were 38 total winners were selected by a panel of AI and subject matter experts.
Here's how seven award-winning companies distinguish their AI models from the hype cycle:
Several health care companies received AI Impact awards for their significant contributions to the industry.
Several health care companies received AI Impact awards for their significant contributions to the industry.
Newsweek Illustration
AI Health Care, Best Outcomes, Care Coordination – Xsolis
Xsolis has created a suite of AI solutions to better connect health care providers with payer organizations and health plans. It serves more than 500 hospitals and health systems and 18 health plans nationwide—and is rapidly expanding its market share, securing spots on the Inc. 5000 and the Deloitte Tech Fast 500 for the fastest growing private companies.
To measure impact, Xsolis tracks the number of cases that are denied and overturned by insurance companies, according to Dr. Heather Bassett, the company's chief medical officer.
"We're able to show our clients, through the use of our AI and other analytics, that they were able to appropriately capture revenue based on the medical intensity of their patient population," Bassett told Newsweek. "Today, we're at about $1.5 billion that we've either protected or helped our clients appropriately capture [across our company's lifetime]."
Since most hospitals are understaffed, they aren't always able to fight every claim and maximize their reimbursements, she added. Xsolis' tool boosts the efficiency of utilization management teams by approximately 20 percent, allowing them to review a larger share of cases.
AI Health Care, Best Outcomes, Health Equity – Bunkerhill Health
"For us, it's actually fairly easy to quantify impact," Nishith Khandwala, co-founder and CEO of Bunkerhill Health, told Newsweek.
The company uses AI to identify clinically significant findings that are hidden in patient records, and ensure that patients receive the follow-up care they need to prevent future complications. For example, a patient might get into a car accident and receive a CT scan to check for cracked ribs. The CT scan might also find signs of coronary artery disease—but in today's medical system, those findings would never be flagged because they weren't relevant to the car crash.
Bunkerhill Health tracks success by counting the number of patients that it flags for a separate encounter with a specialist, like a cardiologist or an oncologist.
"In our office, we have a counter," Khandwala said. "Every time we find a patient who we discovered to have high risk for some other problem, we increment that counter, because that's the number of lives that we have impacted."
AI Health Care, Best Outcomes, Patient Care – Cera
Based in the United Kingdom, Cera is harnessing technology and AI to predict and prevent avoidable falls and hospitalizations in the elderly population. Its ecosystem includes a proprietary app that allows health care staff, patients and families to log health indicators in real time, along with two AI models.
The first, Falls Prevention AI, predicts 83 percent of falls up to seven days in advance—allowing health care staff to intervene and prevent the leading cause of hospitalizations in adults over age 65. The second, its Hospitalization Predict-Prevent tool, predicts three-quarters of hospitalizations one week in advance.
Together, the pair of AI tools flag up to 5,000 high-risk alerts each day, according to Cera founder and CEO Dr. Ben Maruthappu. Data like this shows the impact that the tools are having on patient safety (and on the U.K.'s health system, which spends over £2.3 billion per year on falls in the over-65 population).
"Most importantly of all, we are using AI to make an impact at scale," Maruthappu told Newsweek. "Cera works with over a hundred U.K. Local Governments and the majority of NHS regions, reducing costs, transforming life for patients, and bringing healthcare services into the future."
AI Health Care, Best Outcomes, Diagnostics – Color Health
Color Health is the largest virtual cancer clinic in the United States, created in partnership with the American Cancer Society. Last summer, it teamed up with OpenAI to develop its Cancer Copilot: a novel AI architecture that creates accurate clinical recommendations for clinicians, expanding access to world-class oncology expertise for doctors working at major cancer centers, small community health facilities and every setting in between.
The company primarily charts AI impact in two ways, co-founder and CEO Othman Laraki told Newsweek. First, it tracks how much time clinicians save by using the AI tool. Traditionally, nurses and oncologists had to spend 1-2 hours looking through a patient chart and determining how to prepare them for treatment, Laraki said. Using AI, they can craft the same plan in just 15 minutes.
Additionally, Color Health measures how, when and why clinicians opt to change the output of the AI model. The company's most recent data shows that physicians choose to make changes in less than two percent of the clinical decision factors suggested by the model. Most of those changes had to do with formatting, Laraki added; the model has an error rate under one percent.
"It's performing way better than anything that we've seen published so far," Laraki said. "And it's not because we're using better models—we're using standard open AI release models—but it's because of this architecture that makes the model behave in a very predictable way."
AI Health Care, Best Outcomes, Physician Satisfaction – Iodine Software
At Iodine Software, impact is measured in reimbursement gains, along with improvements in productivity and physician satisfaction, according to co-founder and CEO William Chan.
The company utilizes AI to automate the middle of the revenue cycle, which traditionally requires nurses and physicians to manually collect, interpret and analyze patient data. By inserting AI into the process, Iodine Software paints a more complete clinical picture for insurance companies, ultimately resulting in fewer denials and more accurate reimbursements to health systems. Across all of Iodine's 1,000 hospital clients, that rightsizing yields a cumulative $2.4 billion per year, Chan told Newsweek.
Iodine Software also saves time for health care providers, cutting the time spent reviewing patient case records by "at least half," Chan said. Since the AI model presents information in a concise, precise and actionable way, physicians can respond to information requests more quickly. Clarification asks that once took three days to answer have been whittled down to two hours, in some instances.
"Physicians love that interaction compared to what it was previously," Chan said.
Best of – Most Innovative AI Technology or Service, Extraordinary Impact in AI Innovation – Phare Bio
In 2020, researchers at the Collins Lab at MIT made a landmark discovery when they used AI to identify a new class of antibiotics. Phare Bio was born from that breakthrough, and has since leveraged AI to uncover two additional novel antibiotic classes.
The company's model prioritizes the superbugs identified as the most dangerous by the CDC and the WHO, and predicts drug efficacy, toxicity and pharmacokinetics with high accuracy. Phare Bio has also developed AIBiotics, a generative AI platform that designs new antibiotics.
Ultimately, the company aims to improve the efficiency of antibiotic research and development, according to Dr. Akhila Kosaraju, its president and CEO.
How does it measure that? Ultimately, by "taking better and fewer shots on goal," Kosaraju told Newsweek. It often costs between $1.3 and $1.5 billion to get a single drug over the finish line for FDA approval.
"Those numbers are so high [because they] encompass all of the failures along the way to get to that one exceptional drug," Kosaraju said. "If we can reduce the number of shots on goal substantially, we can half or quarter the cost and time to get these drugs into clinical trials, and then ultimately to be FDA-approved."
AI Education, Best Outcomes, Higher Education – MedCerts
MedCerts has integrated conversational AI, generative AI and natural language processing into its training programs for health care and IT students. Now, students can interact with virtual patients who respond and adapt to their input in real time.
One of the company's major innovations was an in-house AI program for certified nursing assistants (CNAs), designed to develop and assess soft skills like empathy, communication and problem-solving. Traditionally, these skills have been tough to measure—but with MedCerts' AI model, students can practice responding to high-pressure situations in a safe, yet nuanced environment.
Student engagement is a primary indicator of an educational tool's impact, according to Dana Janssen, MedCerts' chief product officer. AI has enabled the company to give students a more interactive experience and bolster their chances of success.
"One of the biggest KPIs for us is program completion, because you can't get certified and you can't get a job without first completing your programs," Janssen told Newsweek. "The more engaging we can make our content or our training—the more interactive—the more effective it ultimately is."
To see the full list of AI Impact winners, visit the official page for Newsweek's AI Impact Awards.
Newsweek will continue the conversation on meaningful AI innovations at our AI Impact Summit from June 23 to 25 in Sonoma, California. Click here to follow along on the live blog.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Meta Just Paid $250M To Lure This 24-year-old AI Whiz Kid: A Strategic Move Or A Power Play?
Meta Platforms Inc. (NASDAQ:META) has reportedly invested a staggering $250 million to secure the talents of 24-year-old AI prodigy, Matt Deitke. What Happened: Deitke, a former doctoral student at the University of Washington, initially turned down Meta CEO Mark Zuckerberg's offer of around $125 million over four years. However, following a meeting with Zuckerberg, Deitke accepted a revised offer of approximately $250 million, with the potential to earn $100 million in the first year alone. As per the report by New York Post, this high-profile recruitment underscores Meta's aggressive strategy in acquiring AI talent. The company has reportedly spent over $1 billion to assemble a team of industry heavyweights, including former Apple AI models team leader, Ruoming Pang. Meta's capital expenditures are projected to surge to $72 billion in 2025, marking a $30 billion increase from the previous year. Also Read: Mark Zuckerberg Poaches Sam Altman's Talent With Multimillion-Dollar Offers To Build Meta's AI Team Deitke has gained recognition in the AI research community through his work at Seattle's Allen Institute for Artificial Intelligence and his co-founded startup, Vercept. His research on multimodal systems aligns with Meta's strategic interests. Why It Matters: While Meta's recruitment of top-tier AI talent could fuel innovation, it has also sparked concerns about increasing economic inequality and the concentration of power in AI development. Critics have lambasted companies like Meta for awarding huge sums to a select few elite researchers while simultaneously laying off thousands of workers. As Meta continues to invest heavily in AI, the implications of this strategy on the broader tech industry and society at large remain to be seen. The recruitment of Deitke and other top AI talents is a clear indication of Meta's commitment to AI, but whether this will translate into sustainable success or exacerbate existing inequalities is a question that will unfold in time. Read Next Meta Exec Dismisses OpenAI's Sam Altman's Claims of $100 Million Signing Bonuses: 'Sam Is Just Being Dishonest Here' UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Meta Just Paid $250M To Lure This 24-year-old AI Whiz Kid: A Strategic Move Or A Power Play? originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
Nvidia CEO Jensen Huang Just Gave Meta Investors Great News -- or Did He?
Key Points Over the last several weeks, Meta has been offering top artificial intelligence (AI) researchers lucrative contracts. These people are now part of Meta Superintelligence Labs, a division focused on competing directly with OpenAI and others. Jensen Huang appears to be supportive of Meta's hiring strategy, but there's a catch. 10 stocks we like better than Meta Platforms › Every few decades, the technology world is reshaped by a generational visionary who somehow seems to see the future before it actually unfolds. Right now, the most important technologist might just be Jensen Huang, the CEO of Nvidia (NASDAQ: NVDA). Huang does not understand artificial intelligence (AI) purely from a technical perspective. The way he speaks about it is more cerebral. Beyond Huang, another technological visionary who is worth paying close attention to is Mark Zuckerberg, the CEO of Meta Platforms. Over the last several weeks, Meta has reportedly been on an aggressive hiring campaign, poaching top AI researchers from OpenAI, Alphabet, GitHub, and Apple. Huang recently addressed Meta's hiring strategy during a discussion at the All-In Summit, hosted by billionaire venture capitalist Chamath Palihapitiya. While Huang's comments about Meta sounded supportive overall, I think there are some key nuances to point out as Zuckerberg seeks to take on competition in the AI realm. Let's dig into Huang's comments and assess what could be in the cards for Meta investors. What did Huang just say about Meta? In a video clip shared on social media, Huang shares his thoughts around Meta's recent hiring spree and the reported hundred-million-dollar signing bonuses. Huang said that a team of roughly 150 researchers and appropriate funding could potentially go on to build a rival platform to OpenAI's ChatGPT. To back up his claim, he explained that several existing AI models that compete with ChatGPT were built by a team of similar size to what Zuckerberg is reportedly assembling through the creation of Meta Superintelligence Labs (MSL). On the surface, this sounds like Meta just earned a vote of confidence from Nvidia, once referred to as the "godfather of AI." But is that really the case? I think there might be more than meets the eye to Huang's comments. What Huang didn't say As a private company, OpenAI is not required to publish its financials or operating metrics. However, according to reports from CNBC, OpenAI now has 3 million paying enterprise customers and $10 billion in annual recurring revenue (ARR). To put this into perspective, OpenAI's ARR was estimated to be around $5.5 billion last year. Those numbers show the company has nearly doubled its ARR base in less than a year, underscoring OpenAI's ability to acquire customers and accelerate its growth trends despite intensified competition from other large language models (LLM) from Anthropic, DeepSeek, and Alphabet, for example. These nuances matter because Meta Superintelligence Labs won't just need to launch something, it will need to prove that it can weather challenges across product execution, customer acquisition, and competing with incumbents with strong first-mover advantages. Although Huang appears confident that more companies will introduce products that compete directly with OpenAI, I would say that his comments fall short of an explicit endorsement of Meta, per se. Rather, I think he's more simply implying that Meta has been investing strategically in its quest to conquer the AI landscape. Is Meta stock a buy now? As the chart below illustrates, Meta experienced sizable expansion in its price-to-earnings ratio (P/E) a couple of years ago. During this period, management implemented significant cost reductions, particularly in the metaverse division. It made a strategic decision to reallocate these savings into AI initiatives. Given the trends above, I'd say that investors welcomed the shift from the metaverse to AI and began pricing in some of the upside. However, over the last 18 months, Meta's P/E levels have pulled back considerably. In my eyes, this valuation reset suggests that investors may not fully appreciate the foundation that Zuckerberg and the management team laid a couple of years ago. In other words, the market may have prematurely bought up the stock, only to discount the long-term upside of the AI opportunity now. With the creation of Meta Superintelligence Labs and a roster of all-star talent ready to build and launch new AI-powered services, Meta could be on the cusp of a massive transformation that remains discounted from a valuation standpoint. At its current levels, I see Meta stock as a no-brainer buying opportunity at these prices as I think the company's upside from AI is largely discounted right now. Should you buy stock in Meta Platforms right now? Before you buy stock in Meta Platforms, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Meta Platforms wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Adam Spatacco has positions in Alphabet, Apple, Meta Platforms, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Apple, Meta Platforms, and Nvidia. The Motley Fool has a disclosure policy. Nvidia CEO Jensen Huang Just Gave Meta Investors Great News -- or Did He? was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Teradyne, Inc. (TER): A Bull Case Theory
We came across a bullish thesis on Teradyne, Inc. on Hunterbrook's Substack. In this article, we will summarize the bulls' thesis on TER. Teradyne, Inc.'s share was trading at $107.43 as of July 31st. TER's trailing and forward P/E were 37.31 and 32.15, respectively according to Yahoo Finance. Logistics robots filling packages in a warehouse, preparing for delivery. Hunterbrook Media, in collaboration with Citrini Research, reveals that Teradyne (TER) may be the hidden supplier behind Amazon's highly publicized new warehouse robot, Vulcan. Amazon claims Vulcan marks a major leap in automation, featuring a robotic arm with a 'sense of touch' capable of picking and stowing items at human-like speed. However, buried beneath the headlines is the fact that Vulcan's robotic limbs are actually built by Universal Robots, a Danish company acquired by Teradyne in 2015. Visual evidence from Amazon's own promotional materials clearly shows the Universal Robots logo and Robotiq grippers — accessories tailored specifically for Universal Robots' arms. As Amazon moves to automate 80% of its 14 billion hand-stowed items annually, this could translate to a ~$400 million opportunity for Teradyne's robotics division, which currently accounts for just 10–15% of company revenues. The implications extend beyond Amazon, as the Vulcan's capabilities showcase the progress made by combining AI and robotics. Innovations like vision-language-action models and Nvidia's Isaac Sim — integrated directly into Teradyne's robots — are enabling robots to reason spatially and act with precision in complex environments. Nvidia claims these integrations are 50–80x faster than legacy systems, potentially setting a new standard in industrial automation. Despite slumping shares tied to a cyclical downturn in Teradyne's core semiconductor testing business, this Amazon collaboration signals a pivotal moment. With no recent insider stock sales for the first time since 2018, and earnings around the corner, Teradyne may be on the brink of a robotics-driven revaluation. Previously we covered a bullish thesis on Lam Research Corporation (LRCX) by The Antifragile Investor in May 2025, which highlighted its role in chipmaking, strong service margins, and high switching costs. The company's stock price has appreciated approximately 14.55% since our coverage. This is because the thesis played out as expected. Hunterbrook shares a similar view in its thesis on Teradyne (TER) but emphasizes robotics-led upside. Teradyne, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 49 hedge fund portfolios held TER at the end of the first quarter which was 61 in the previous quarter. While we acknowledge the potential of TER as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data